Product Description
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hungary | India | Ireland | Italy | New Zealand | Russia | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hyperlipoproteinemias|Hyperlipidemia|Dyslipidemia|Type 2 Diabetes|Inflammation|Myocardial Ischemia|Coronary Artery Disease|Oxidative Stress|Hypercholesterolemia|Atherosclerosis
Phase 3: Hypercholesterolemia|Hyperlipidemia|Hyperlipoproteinemias|Dyslipidemia|Hyperlipoproteinemia Type V|Lipidoses|Hyperlipoproteinemia Type II|Type 2 Diabetes|Coronary Disease|Peripheral Arterial Disease|Intermittent Claudication|Stroke|Peripheral Vascular Diseases|Myocardial Infarction|Coronary Artery Disease|Myocardial Ischemia
Phase 2: Dyslipidemia|Rhinitis, Allergic, Seasonal|Hypercholesterolemia|Asthma|Flushing
Phase 1: Dyslipidemia|Hyperlipidemia|Hypercholesterolemia|Type 2 Diabetes|Rosacea|Hyperlipoproteinemia Type II
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NILACH | P4 |
Terminated |
Atherosclerosis |
2014-07-01 |
|
MK-0524A-119 | N/A |
Terminated |
Dyslipidemia|Hypercholesterolemia |
2013-05-01 |
|
2011-000755-17 | P3 |
Terminated |
Coronary Disease |
2013-03-08 |
|
MK-0524A-133 | P3 |
Terminated |
Hypercholesterolemia|Dyslipidemia |
2013-02-26 |